News & Updates
TN-401 AAV9-based Gene Therapy Designed to Deliver Fully Functional PKP2 Gene with the Aim of Increasing Protein Levels to Address Underlying Disease RIDGE-1 Currently Enrolling at Six Centers; Observational Natural History and Seroprevalence Study of PKP2-associated ARVC Adults Continues Enrollment at 20 Clinical Sites in the U.S., UK and Europe Initial Clinical Data for RIDGE-1…
Read More
Excerpt from the Press Release: ALAMEDA, Calif.–(BUSINESS WIRE)–Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, presented preclinical data on its CRISPR X-Editor (XE) and Epigenetic Long-Term X-Repressor (ELXR) technologies at the American Heart Association’s Scientific Sessions 2024. The new data described in Scribe’s late-breaking, oral, and…
Read More
Dose-proportional oral bioavailability without clinical signs, including those associated with hallucinogenic compounds, was demonstrated in rat and dog pharmacokinetic (PK) studies while significant brain penetration was observed in rat Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogen…
Read More
The Study Results are Published in the Journal of Urology Online Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights results from a long-term follow-up study with JELMYTO (mitomycin) for pyelocalyceal solution, which is…
Read More
SAN DIEGO, Nov. 21, 2024 /PRNewswire/ — Breakthrough Genomics, a leader in the clinical analysis of genomic data and early cancer diagnostics, announced today its collaboration with the PRECEDE Consortium to advance the clinical evaluation and adoption of its BT-Reveal™ Early Pancreatic Cancer Test. Excerpt from the Press Release: This groundbreaking blood test, which is powered…
Read More
The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025 Phase III Clinical Trial is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer Excerpt from the Press Release:…
Read More
Data presented at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer Results bolster Company’s rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients undergoing CAR T cell therapy Excerpt from the Press Release: FRAMINGHAM, MA / ACCESSWIRE / November 21,…
Read More
We are thrilled to announce this significant milestone in the clinical investigation of ABI-110″ said Shawn Liu, Ph.D., Chief Executive Officer of Avirmax Biopharma Inc. “ABI-110 has the potential to revolutionize the treatment landscape for Wet AMD and PCV.” Excerpt from the Press Release: HAYWARD, Calif., Nov. 21, 2024 /PRNewswire/ — Avirmax Biopharma, Inc., a leader in the…
Read More
Wistar Institute Researchers Discover New Combination Therapy Approach for Metastatic Ovarian Cancer
Zhang Lab Demonstrates Novel Combination of Beta Glucan and Interferon Gamma Results in Tumor Regression Excerpt from the Press Release: PHILADELPHIA — (November 21, 2024) — The Wistar Institute’s Nan Zhang, Ph.D., assistant professor in the Ellen and Ronald Caplan Cancer Center’s Molecular and Cellular Oncogenesis Program, and lab have discovered a new approach to treating ovarian…
Read More
Drs. Pankaj Mohan, CEO of Sonnet, and John Cini, CSO of Sonnet, discuss the Company’s recent issuance of a U.S. patent covering a variant of IL-18 incorporated into two novel immunotherapeutic drug candidates, SON-1400 and SON-1411 Watch the “What this Means” segment here Excerpt from the Press Release: PRINCETON, NJ, Nov. 12, 2024 (GLOBE NEWSWIRE)…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?